Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 10/20 | 0.69 |
| ▸ | DRD1 | P21728 | 4/20 | 0.69 |
| ▸ | DRD2 | P14416 | 6/20 | 0.67 |
| ▸ | DRD5 | P21918 | 2/20 | 0.59 |
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | HTR7 | P34969 | 2/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711653 | 0.84 | DRD3 (0.62) | DRD3DRD1DRD2DRD5HTR1A | |
| SCHEMBL6711558 | 0.82 | DRD3 (0.56) | DRD3DRD1DRD2DRD5HTR1A | |
| SCHEMBL13711971 | 0.81 | KCNH2 (0.71) | DRD3DRD1DRD2DRD5HTR1A | |
| SCHEMBL2518183 | 0.80 | ADRA1D (0.71) | DRD3DRD1DRD2HTR1AHTR7 | |
| SCHEMBL9050587 | 0.80 | DRD3 (0.56) | DRD3DRD1DRD2HTR1AHTR7 | |
| SCHEMBL6714657 | 0.79 | HRH4 (0.55) | DRD3DRD2DRD5HTR1AHTR7 | |
| SCHEMBL6972081 | 0.79 | DRD3 (0.57) | DRD3DRD1DRD2DRD5HTR1A | |
| Hydrochloric Acid SCHEMBL6712934 | 0.78 | DRD3 (0.56) | DRD3DRD1DRD2DRD5HTR1A | |
| SCHEMBL18301489 | 0.78 | KCNH2 (0.64) | DRD3DRD1DRD2DRD5HTR1A | |
| SCHEMBL30073110 | 0.78 | KDM4E (0.72) | DRD3DRD2DRD5HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138203-A1 | Bicyclic lactams and sulfonamides with 5-ht1a -affinity and use thereof for preventing and treating cerebral ischaemia | STEINER GERD | 2004-07-15 | — | — | US | disclosed |
| EP-1296954-A1 | BICYCLIC LACTAMS AND SULFONAMIDES WITH 5-HT1A-AFFINITY AND USE THEREOF FOR PREVENTING AND TREATING CEREBRAL ISCHAEMIA | Abbott GmbH & Co. KG (DE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002002529-A1 | BICYCLIC LACTAMS AND SULFONAMIDES WITH 5-HT1A-AFFINITY AND USE THEREOF FOR PREVENTING AND TREATING CEREBRAL ISCHAEMIA | ABBOTT GMBH & CO. KG (DE) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138203-A1 | Bicyclic lactams and sulfonamides with 5-ht1a -affinity and use thereof for preventing and treating cerebral ischaemia | HTR1A, HTR5A, HTR2C | DRD3 178/4885DRD1 113/4885DRD2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.